<DOC>
	<DOCNO>NCT00075595</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil , leucovorin , irinotecan , use different way stop tumor cell divide stop grow die . Giving one chemotherapy drug may kill tumor cell . PURPOSE : This phase II trial study well give fluorouracil together leucovorin irinotecan work treat patient recurrent refractory metastatic unresectable colorectal cancer .</brief_summary>
	<brief_title>Fluorouracil , Leucovorin , Irinotecan Treating Patients With Recurrent Refractory Metastatic Unresectable Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine time progression time death progression patient recurrent refractory metastatic unresectable colorectal cancer treat fluorouracil , leucovorin calcium , irinotecan . Secondary - Determine objective response stabilization rate patient treat regimen . - Determine time treatment failure patient treat regimen . - Determine duration response patient treat regimen . - Determine overall survival rate patient treat regimen . - Determine incidence grade 3 4 toxicity patient treated regimen . OUTLINE : This open-label , multicenter study . Patients receive leucovorin calcium IV 2 hour day 1 , irinotecan IV 1 hour day 1 3 , fluorouracil IV continuously 46 hour begin day 1 . Courses repeat every 2 week absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 78 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal adenocarcinoma Metastatic , unresectable disease Meets 1 follow criterion : At least 1 unidimensionally measurable metastatic lesion least 10 mm spiral scan OR 20 mm conventional scan Evaluable disease Evidence disease ( e.g. , ascites bone metastasis ) image technique Progressive disease define 1 follow criterion : Progressive disease receive firstline chemotherapy Recurrent disease within 6 month complete adjuvant chemotherapy No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age 18 80 Performance status WHO 02 Life expectancy At least 3 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin &lt; 1.5 time upper limit normal ( ULN ) Alkaline phosphatase &lt; 3 time ULN Renal Not specify Cardiovascular No uncontrolled angina No myocardial infarction within past 6 month Gastrointestinal No chronic diarrhea grade 2 great No unresolved fully partially obstruct intestine Other Not pregnant nursing Fertile patient must use effective contraception No underlying disease medical condition would preclude study participation No prior malignancy except curatively treat basal cell cancer carcinoma situ cervix No psychological , social , familial , geographical condition would preclude study followup PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No prior irinotecan Endocrine therapy Not specify Radiotherapy At least 3 week since prior radiotherapy Surgery At least 3 week since prior surgery Other No concurrent clinical trial participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>